11th IAS Conference on HIV Science (IAS 2021), Berlin, Germany, 18-21 July 2021

第 11 届 IAS HIV 科学会议 (IAS 2021)，德国柏林，2021 年 7 月 18-21 日

• 批准号: 10254560
• 负责人: Christopher C. Beyrer
• 金额: $ 75万
• 依托单位: IAS
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-06-09 至 2022-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10254560
• 关键词: 2019-nCoV; AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adherence; Adolescent and Young Adult; Adult; Affect; Africa; Africa South of the Sahara; Age; Aging; Antiviral Agents; Basic Science; Behavioral; Behavioral Sciences; Berlin; COVID-19; COVID-19 pandemic; COVID-19 vaccine; Caring; Child; Childhood; Chronic; Cities; Clinical; Clinical Research; Clinical Sciences; Communities; Complex; Contraceptive Agents; Contraceptive methods; Counseling; Country; Coupled; Data; Development; Discrimination; Disease; Disease Progression; Disease remission; Eastern Europe; Emergency response; Ensure; Epidemic; Europe; Failure; Fatigue; Financial Support; Formulation; Fostering; Futility; Gays; Germany; HIV; HIV Vaccine Trials Network; HIV vaccine; HIV/TB; Health; Health Resources; Health Services Accessibility; Health system; Heart; Homophobia; Human; Human immunodeficiency virus test; Immunology; Incidence; Incidence Study; Infant; Infection; Injectable; Injecting drug user; Integrase Inhibitors; International AIDS; Interruption; Intervention; Knowledge; Leadership; Life; Minority; Modality; Morbidity - disease rate; Multi-Drug Resistance; Opiate Addiction; Outcome; Pathogenesis; Patients; Persons; Population; Positioning Attribute; Prevention; Prevention Research; Prevention approach; Prevention program; Preventive vaccine; Public Health; Recording of previous events; Regimen; Relative Risks; Reporting; Research; Research Personnel; Resources; Rights; Risk Reduction; SARS-CoV-2 infection; Safety; Science; Scientist; Social Sciences; Structure; Technology; Testing; Ukraine; Uncertainty; Update; Vaccines; Variant; Viral hepatitis; Virus Diseases; War; Woman; Work; base; body system; clinical care; co-infection; community engagement; comorbidity; density; efficacy trial; implementation science; improved; innovation; insight; interdisciplinary collaboration; low and middle-income countries; marginalized population; men; men who have sex with men; mortality; multidisciplinary; novel; pandemic disease; patient oriented; person centered; pill; pre-exposure prophylaxis; precision medicine; preventive intervention; programs; public health emergency; racial and ethnic disparities; reproductive; response; social stigma; social structure; symposium; synergism; tool; transgender women; transmission process; transphobia; treatment program; virology; virtual; virtual delivery

Project Summary The scientific and public health response against HIV/AIDS in the past four decades has been remarkable and unprecedented. Yet HIV transmission continues in many populations at unacceptably high rates despite testing and treatment availability, largely driven by stigma and discrimination and other social and structural determinants. IAS 2021 will be the key global scientific convening to review progress against remaining challenges in controlling the epidemic. Significant new insights that are expected to be shared at IAS 2021 include basic work on virology, immunology and HIV pathogenesis with a continued focus on the functional cure/remission agenda. Clinical research in HIV is entering a new era of longer acting and injectable formulations which will be highlighted at IAS 2021, along with the remaining challenges of adherence, pill fatigue, and multi-drug resistant variants. Pediatric clinical care issues will be a further key topic where the advances in newer integrase inhibitor-based regimens for infants and children will be a primary focus. In the prevention field, the finding of superiority for long-acting injectable cabotegravir as PrEP marks the beginning of a new era, with further evidence expected in this regard at IAS 2021, along with early data on the co-formulations of long-acting injectables with other products for contraception, opioid dependence, and other health conditions. In the implementation science field innovative testing, prevention, treatment, and surveillance modalities will feature prominently at IAS 2021. Finally, the COVID-19 pandemic is expected to be among the defining themes across all scientific tracks against the background of treatment interruptions worldwide and the many remaining uncertainties regarding HIV/SARS- CoV-2 interactions. While the IAS is making parallel provisions for shifting to a fully virtual delivery format if mandated by the state of the COVID-19 pandemic, IAS 2021 is planned to take place in Berlin from 18-21 July 2021, with a strong virtual presence to ensure broad access (expected attendance of 6,000 delegates). It will provide a critical platform for HIV science to re-convene in a country now characterized by a celebration of diversity and zero discrimination. Berlin is at the heart of Europe, with close connectivity to the most HIV-affected region in Europe—Central and Eastern Europe, in particular Ukraine, and the Russian Federation, where, in marked contrast to Germany, rights-based approaches to HIV programming are constantly challenged. Specific aims of IAS 2021 are to: 1. Accelerate basic science and clinical innovation for the development and application of person-centered, precision medicine for HIV, including pathogenesis, transmission, vaccines, remission and a functional cure. 2. Advance inter-disciplinary collaboration in clinical research to improve integrated care across all life stages and accelerate updates to treatment guidance especially for low and middle-income countries, infected children, persons with HIV, TB, viral hepatitis and COVID-19 infection; 3. Strengthen HIV prevention research to improve biomedical, behavioral and structural interventions and the integration of new tools, including long-acting injectable prevention technologies in prevention programs for those in need; 4. Advance core components of the implementation science agenda across the HIV prevention-to-care cascade in the COVID-19 era, including aspects of integration and approaches for meaningful community engagement and resourcing health systems; 5. Address HIV vulnerability and determinants of disease progression among key and marginalized populations, including novel interventions and implementation science to reduce stigma and discrimination, including intersectional stigmas of HIV, other diseases, homophobia, transphobia, and ethnic and racial disparities. The scientific program will consist of four tracks: Track A – Basic Science; Track B – Clinical Science; Track C – Prevention Science; and Track D – Social, Behavioral, and Implementation Science. Cross-cutting aspects will be covered in plenary talks that also connect the scientific tracks with community and leadership perspectives, and bridging sessions will cut across at least two of the tracks to provide opportunities for multi-disciplinary dialogues. The participation of young researchers, basic scientists and researchers in related fields such as non- communicable diseases will be strengthened by active solicitation of relevant science and the provision of specific financial support, in addition to increased remote-access options.

项目摘要 在过去的四十年中，对艾滋病毒/艾滋病的科学和公共卫生反应非常出色， 空前的。然而，在许多人群中，艾滋病毒传播继续以不可接受的高率目的地测试 以及治疗可用性，主要是受污名和歧视以及其他社会和结构的驱动 决定因素。 IAS 2021将是审查反对剩余的进度的全球关键科学召集 控制流行病方面的挑战。 预计将在IAS 2021上共享的重要新见解包括病毒学，免疫学的基本工作 和HIV发病机理，继续关注功能治愈/缓解议程。艾滋病毒的临床研究 正在进入一个更长的表演和可注射公式的新时代 遵循依从性，丸疲劳和多药抗性变体的挑战。小儿临床护理 问题将是另一个关键主题，在该问题中，新的集成酶抑制剂基于婴儿和的方案的进步 孩子将是主要重点。在预防领域，对长效注射的优势发现 Cabotegravir作为准备标志着一个新时代的开始，在这方面有进一步的证据 2021年，以及有关长效注射量与其他产品的共同形成的早期数据 避孕，阿片类药物依赖和其他健康状况。在实施科学领域创新 测试，预防，治疗和监视方式将在IAS 2021中以显着特征。最后， 预计COVID-19大流行将成为所有科学曲目中的定义主题之一 全球治疗中断的背景以及有关HIV/SARS-的剩余许多不确定性 COV-2相互作用。 当国际委员会制定并行规定，以转移到完全虚拟交付格式的情况下，如果国家要求 在1921年7月18日至21日，计划在柏林举行IAS 2021年的IAS 2021年，其强劲 虚拟存在以确保广泛访问（预期的6,000名代表）。它将提供关键 艾滋病毒科学平台在一个以多样性庆祝和零为特征的国家中重新连接的平台 歧视。柏林处于欧洲的核心，与最受艾滋病毒影响最大的地区的连通性 欧洲 - 中国和东欧，尤其是乌克兰和俄罗斯联邦，在那里有标记 与德国形成鲜明对比的是，基于权利的艾滋病毒计划的方法经常受到挑战。 IAS 2021的具体目标是： 1。加速基础科学和临床创新，以发展和应用以人为中心， 艾滋病毒的精密药物，包括发病机理，传播，疫苗，缓解和功能治愈。 2。在临床研究方面提前学科合作，以改善各个生活阶段的综合护理 并加速对治疗指导的更新，尤其是针对低收入和中等收入国家的更新 儿童，艾滋病毒，结核病患者，病毒性肝炎和互联-19感染； 3。加强艾滋病毒预防研究，以改善生物医学，行为和结构干预措施以及 集成新工具，包括预防计划中的长效预防技术 有需要的人； 4。实施科学议程的提前核心组成部分，预防艾滋病毒至护理级联 在Covid-19时代，包括整合的各个方面和有意义社区的方法 参与和恢复卫生系统； 5。解决艾滋病毒的脆弱性，并确定关键和边缘化人群之间的疾病进展， 包括新颖的干预措施和实施科学，以减少污名和歧视，包括 艾滋病毒，其他疾病，同性恋恐惧症，恐惧症以及种族和种族差异的交叉污名。 科学计划将由四个曲目组成：跟踪A - 基础科学；轨道B - 临床科学；轨道c - 预防科学；和轨道D - 社会，行为和实施科学。横切方面将会 被全体会谈所涵盖，也将科学轨道与社区和领导观点联系起来， 桥接会议将跨越至少两个轨道，为多学科提供机会 对话。年轻研究人员，基础科学家和研究人员参与相关领域，例如非 - 通过积极的相关科学和提供，可以加强可传播的疾病 除了增加远程访问选项外，具体的财务支持。